跳至主要内容
临床试验/NL-OMON48600
NL-OMON48600已完成不适用

Correlation between endogenous DPD substrate concentrations and the pharmacokinetics and toxicity of 5-fluorouracil in patients with colorectal or pancreas cancer - FUUT

Catharina-ziekenhuis0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational invasive

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1) Pathologically confirmed malignancy for which treatment with 5-FU is
  • indicated in the FOLFOX, FOLFIRI or FOLFIRINOX regimen.
  • 2) Minimal acceptable safety laboratory values defined as
  • a. ANC of * 1.5 x 109 /L
  • b. Platelet count of * 100 x 109 /L
  • c. Hepatic function as defined by serum bilirubin * 1.5 x ULN, ALAT and ASAT *
  • 2.5 x ULN; in case of liver metastases ALAT and ASAT * 5 x ULN.
  • d. renal function as defined by MDRD >30 ml/min

排除标准

  • 1. Patients with known substance abuse, psychotic disorders, and/or other
  • diseases expected to interfere with study or the patient*s safety
  • 2. Women who are pregnant or breast feeding
  • 3. Patients in whom the bolus injection will be skipped due to e.g. toxicity of
  • previous chemo therapy regimen.

研究者

相似试验

Correlation between endogenous DPD substrate... | 临床试验